An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma
This study has been completed.
Information provided by:
First received: December 1, 2004
Last updated: January 21, 2010
Last verified: January 2010
A study to determine the safety, tolerability, and anti-tumor effectiveness of an oral investigational drug in the treatment of relapsed diffuse large B-cell lymphoma.
Drug: MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)|
Resource links provided by NLM:
Further study details as provided by Merck:
Primary Outcome Measures:
- Objective response rate based on FDG-PET and CT scan findings.
Secondary Outcome Measures:
- Response duration, Progression-free survival, Time to progression, Time to response, 3-Month and 6-month progression free survival.
|Study Start Date:||May 2005|
|Primary Completion Date:||July 2006 (Final data collection date for primary outcome measure)|
Contacts and Locations